Company Overview and News

 
Greater KL region draws in RM4.5bil investments from MNCs

2018-03-30 thestar.com.my
Meanwhile, InvestKL has a target to attract 10 MNCs this year, its chief executive officer Datuk Zainal Amanshah said in the same statement.
Upvote Downvote

 
InvestKL: Malaysians take up most high-skill jobs in 73 MNCs

2018-03-29 themalaymailonline
Up to last year, InvestKL said it has succeeded in drawing 73 multinational companies into the capital city with up to RM4.5 billion worth of investments. — AFP picKUALA LUMPUR, March 29 ― More than two-thirds of 5,381 professional jobs offered by multinational companies were filled by locals, InvestKL said today.
Upvote Downvote

 
France signs deals worth $16 billion in India; to deepen defense, security ties

2018-03-10 reuters
PARIS/NEW DELHI (Reuters) - French and Indian companies signed contracts worth 13 billion euros ($16 billion) on the first day of President Emmanuel Macron’s visit to India on Saturday, the French presidency said in a statement.
Upvote Downvote

 
France signs deals worth $16 billion in India, Macron's office says

2018-03-10 in.reuters
PARIS (Reuters) - French and Indian companies signed contracts worth 13 billion euros ($16 billion) on the first day of President Emmanuel Macron’s visit to India on Saturday, the French presidency said in a statement.
Upvote Downvote

 
Linde, Praxair expect bids for planned divestitures this month: sources

2018-03-08 channelnewsasia
Gases groups Linde and Praxair are pressing ahead with divestitures to facilitate their planned US$85 billion merger and have asked potential buyers to present first-round bids this month, people close to the matter said.
Upvote Downvote

 
Linde, Praxair expect bids for planned divestitures this month: sources

2018-03-08 reuters
FRANKFURT/BRUSSELS (Reuters) - Gases groups Linde (LING.DE) and Praxair (PX.N) are pressing ahead with divestitures to facilitate their planned $85 billion merger and have asked potential buyers to present first-round bids this month, people close to the matter said.
Upvote Downvote

 
Plug Power: Q4 And FY2017 Takeaways

2018-03-08 seekingalpha
Q4 results largely in line with preliminary numbers released in conjunction with the company's business update in February.
Upvote Downvote

1
Plug Power's (PLUG) CEO Andy Marsh on Q4 2017 Results - Earnings Call Transcript

2018-03-07 seekingalpha
Greetings, and welcome to the Plug Power’s Fourth Quarter and Year End 2017 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Upvote Downvote

 
Investors bet on component makers in electric car shift

2018-03-07 reuters
LONDON (Reuters) - As carmakers ramp up spending on self-driving and electric vehicles (EVs), many investors are betting their component suppliers will be the first winners from the technology shifts.
Upvote Downvote

 
Investors bet on component makers in electric car shift - Channel NewsAsia

2018-03-07 channelnewsasia
As carmakers ramp up spending on self-driving and electric vehicles (EVs), many investors are betting their component suppliers will be the first winners from the technology shifts.
Upvote Downvote

 
Japan car giants team up to build hydrogen stations

2018-03-05 yahoo
Top Japanese carmakers said on Monday they were teaming up to nearly double the amount of hydrogen stations in Japan, as the car-mad country seeks to head off competition from China and Germany.
Upvote Downvote

 
Flash - Japan car giants team up to build hydrogen stations - France 24

2018-03-05 france24
Top Japanese carmakers said on Monday they were teaming up to nearly double the amount of hydrogen stations in Japan, as the car-mad country seeks to head off competition from China and Germany.
Upvote Downvote

 
Japan car giants team up to build hydrogen stations

2018-03-05 newsinfo.inquirer.net
Japan H2 Mobility President Hideki Sugawara delivers a speech during a press conference in Tokyo on March 5, 2018. The below-mentioned 11 companies announced joint establishment of Japan H2 Mobility (JHyM) aimed at the full-fledged development of hydrogen stations for fuel cell vehicles (FCV) in Japan. Image: Kazuhiro Nogi / AFP
Upvote Downvote

 
Linde, Praxair Kick Off $8 Billion in Asset Sales - Bloomberg

2018-03-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Sasol Limited's (SSL) CEOs Stephen Cornell and Bongani Nqwababa on Q2 2018 Results - Earnings Call Transcript

2018-02-27 seekingalpha
Please standby, we are about to begin. Good morning, and good afternoon, ladies and gentlemen, and welcome to the Sasol Results Conference Call. Today's call will be hosted by Stephen Cornell and Bongani Nqwababa, Joint President and Chief Executive Officers; and Paul Victor, Chief Financial Officer. Following the presentations, an interactive Q&A session will take place. [Operator Instructions]
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...